FDA committee supports Aventis' Sculptra for sunken facial features from HIV

An FDA panel gave its blessing to Aventis' Sculptra injection for treating a byproduct of HIV, likely leading to eventual agency approval for the drug, the first for filling in sunken facial features. Panel members said the drug, already approved in Europe as New-Fill, has shown convincing evidence of safety and effectiveness, although some FDA panel members raised concerns about the lack of testing on large numbers of women and minorities and about the drug's possible off-label cosmetic applications.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD